We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300442:SZSERange Intelligent Computing Technology Group Company Limited Class A Analysis

Data as of 2026-03-16 - not real-time

CN¥83.32

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Range Intelligent Computing posted a solid 14.6% revenue growth and an impressive 36.4% operating margin, driving a stellar 39% ROE, which underscores the business’s strong profitability fundamentals. However, the balance sheet is strained with a debt‑to‑equity ratio of 135% and negative free cash flow of over CNY 4.3 billion, raising concerns about cash sustainability. On the technical side, the stock trades at CNY 83.32, below the 20‑day SMA of 88.89 but above the 50‑day SMA of 78.99, while the MACD has turned bearish and the RSI sits near the neutral 45 level. Volume is increasing and volatility is high at 79%, yet beta is low, indicating limited market‑wide price sensitivity. The DCF fair value of roughly CNY 29.9 and a -20% upside/downside metric signal that the market is pricing the shares at a substantial premium, reinforced by an “Extreme Greed” sentiment reading. In summary, the company’s growth and margins are attractive, but valuation, leverage, and cash‑flow pressures make the current price risky.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and price below 20‑day SMA
  • Significant overvaluation relative to DCF fair value
  • High 30‑day volatility and extreme greed sentiment

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong operating margins and ROE supporting earnings stability
  • Elevated debt levels and negative free cash flow limiting upside
  • Increasing trading volume indicating continued market interest

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Growth potential in China’s IDC and AIDC markets
  • Regulatory environment for Chinese tech firms remains uncertain
  • Need for debt reduction and cash‑flow improvement to justify valuation

Key Metrics & Analysis

Financial Health

Revenue Growth14.60%
Profit Margin101.95%
P/E Ratio28.7
ROE39.22%
ROA3.44%
Debt/Equity135.27
P/B Ratio10.4
Op. Cash FlowCN¥3.7B
Free Cash FlowCN¥-4344742400
Industry P/E33.7

Technical Analysis

TrendBullish
RSI45.6
SupportCN¥76.50
ResistanceCN¥106.33
MA 20CN¥88.89
MA 50CN¥78.99
MA 200CN¥56.93
MACDBearish
VolumeIncreasing
Fear & Greed Index76.61

Valuation

Fair ValueCN¥29.93
Target PriceCN¥66.49
Upside/Downside-20.20%
GradeOvervalued
TypeBlend
Dividend Yield0.63%

Risk Assessment

Beta0.14
Volatility79.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.